FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC

FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC

FDA priority review advances the belzutifan and pembrolizumab combo

The FDA granted priority review to supplemental applications for belzutifan (Welireg) in combination with pembrolizumab (Keytruda) for the adjuvant treatment of adult patients with renal cell carcinoma. The regulatory decision came on March 2, 2026.

This is a supplemental application review, not a standalone approval. The submissions seek to expand the labeling of both drugs into the adjuvant setting for patients at elevated risk of recurrence after nephrectomy. Priority review status accelerates the FDA's standard review timeline.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for adjuvant renal cell carcinoma, with belzutifan and Welireg most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

LITESPARK-022 results support the adjuvant filing

Belzutifan plus adjuvant pembrolizumab improved disease-free survival compared with pembrolizumab alone in patients with clear cell renal cell carcinoma. The trial, NCT05239728, evaluated oral belzutifan plus intravenous pembrolizumab compared to placebo plus pembrolizumab in participants with clear cell renal cell carcinoma post nephrectomy.

This result provides the clinical foundation for the supplemental applications now under priority review.

IntelligenceCompetitive Intelligence▾

Merck & Co., Inc. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Belzutifan's FDA label provides the regulatory backdrop

Belzutifan is a hypoxia-inducible factor inhibitor manufactured by Merck Sharp & Dohme LLC. The drug is indicated for von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, as well as for advanced renal cell carcinoma with a clear cell component following prior PD-1/PD-L1 inhibitor and VEGF-TKI therapy.

Pembrolizumab received FDA approval on November 17, 2021, for the adjuvant treatment of patients with renal cell carcinoma. The supplemental applications would add an adjuvant indication for the belzutifan and pembrolizumab combination.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for adjuvant renal cell carcinoma. Expect implications for pricing, access, and launch sequencing.

Regulatory pathway and decision timeline

The key event to monitor is the FDA decision on the supplemental applications. Readers should watch for announcements regarding the approval outcome and any label updates tied to the priority review decision.

Additional clinical trials in renal cell carcinoma include NCT07187778 (BLAZE), a Phase II trial of belzutifan or pembrolizumab versus combination as neoadjuvant therapy in clear cell renal cell carcinoma, and NCT07227402 (MK-6482-033), a Phase III trial of belzutifan and zanzalintinib in people with recurrent kidney cancer following adjuvant therapy.

IntelligenceStrategic Takeaways▾

The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma on March 2, 2026. NCT05239728 demonstrated improved disease-free survival with the combination versus pembrolizumab alone in clear cell RCC post nephrectomy. The supplemental applications seek to add an adjuvant indication for the belzutifan and pembrolizumab combination, where pembrolizumab

Key Takeaways

• The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma on March 2, 2026.
• NCT05239728 demonstrated improved disease-free survival with the combination versus pembrolizumab alone in clear cell RCC post nephrectomy.
• The supplemental applications seek to add an adjuvant indication for the belzutifan and pembrolizumab combination, where pembrolizumab already holds an indication.
• Priority review does not guarantee approval; the FDA decision remains the key regulatory milestone.

Frequently Asked Questions

Related profiles

• belzutifan
• pembrolizumab

Related coverage

• FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
• FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
• GSK’s Blenrep returns to the US market after FDA approves resubmission